Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: neuroscience – Page 413

First Human Patient to Receive a Neuralink Brain Implant Used it to Stay Up All Night Playing Civilization 6

The first human recipient of a Neuralink brain implant has shared new details on his recovery and experience of living with the experimental assistive tech, which has allowed him a greater level of freedom and autonomy, including the ability to pull an all-nighter playing Sid Meier’s Civilization 6.

Neuralink co-founder Elon Musk took to X/Twitter in January to reveal that the company had implanted its first brain-computer interface in the head of a human patient, who was “recovering well” following the surgery. The billionaire also hinted at the time that the implant was functioning well and had detected a “promising neuron spike”. In a subsequent February update, Musk commented that the unnamed patient had seemingly made a full recovery, and was even able to use the implant to manipulate a computer cursor with thought alone.

Finally, on March 20, Neuralink posted its own update to X in the form of a nine-minute livestream in which 29-year-old implant recipient Noland Arbaugh used the technology to play a digital version of chess, while discussing how living with the experimental aide had changed his life.

Scientists Discover That “Transcendent” Thinking May Grow Teens’ Brains

Scientists at CANDLE have discovered that adolescents who grapple with the bigger meaning of social situations experience greater brain growth, which predicts stronger identity development and life satisfaction years later.

Scientists at the USC Rossier School of Education’s Center for Affective Neuroscience, Development, Learning and Education (CANDLE), have shown for the first time that a type of thinking, that has been described for over a century as a developmental milestone of adolescence, may grow teenagers’ brains over time.

This kind of thinking, which the study’s authors call “transcendent,” moves beyond reacting to the concrete specifics of social situations to also consider the broader ethical, systems-level, and personal implications at play. Engaging in this type of thinking involves analyzing situations for their deeper meaning, historical contexts, civic significance, and/or underlying ideas.

Scientists can’t decide if consciousness is real or fake

What if everything in our world has a soul and mind? What if every desk, chair, and potted plant has a conscious stream of thoughts? That’s the basic idea behind Panpsychism, a theory first put forward in the late 16th century by Francesco Patrizi. It’s been a hundred years or so since science won out about this theory in the 1920s, but now it’s regaining momentum.

To understand why this theory is regaining popularity requires us to look at one of the most difficult conundrums that human scientists have ever faced: where consciousness comes from. Scientists have been trying to solve this hard problem for over a hundred years, and while developments in neuroscience, psychology, and quantum physics have come far, we still don’t have a definitive answer.

The argument is regaining momentum, though, thanks in part to the work of Italian neuroscientist and psychiatrist Giulio Tononi, who proposed the idea that there is widespread consciousness even found in the simplest of systems. Tononi and American neuroscientist Christof Koch argued that consciousness will follow where there are organized lumps of matter. Some even believe that the stars may be conscious.

From autism to Alzheimer’s: A large-scale animal study links brain pH changes to wide-ranging cognitive issues

A global collaborative research group comprising 131 researchers from 105 laboratories across seven countries has published a paper in eLife. The study identifies brain energy metabolism dysfunction leading to altered pH and lactate levels as common hallmarks in numerous animal models of neuropsychiatric and neurodegenerative disorders, such as intellectual disability, autism spectrum disorders, schizophrenia, bipolar disorder, depressive disorders, and Alzheimer’s disease.

Understanding the link between brain tumour and movement disorder

A brain tumor is the growth of abnormal cells in the brain or the area near it including nerves, pituitary gland, pineal gland, and membranes that cover the surface of the brain. Sometimes it can happen in the brain tissue as well. Brain tumours can be cancerous (malignant) or it can be non-cancerous (benign). However, both of them can be potentially life-threatening.

On the other hand, movement disorders refer to a cluster of neurological conditions that can either cause increased movements or decreased movements. For the unversed, brain tumours that are specifically affecting the brainstem, can sometimes cause various movement disorders.

First three patients in the trial showed dramatic responses within days

A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment. In a paper published today in The New England Journal of Medicine, researchers from the Mass General Cancer Center, a member of the Mass General Brigham healthcare system, shared the results for the first three patient cases from a phase 1 clinical trial evaluating a new approach to CAR-T therapy for glioblastoma (GBM). The trial, known as INCIPIENT, is designed to evaluate the safety of CARv3-TEAM-E T cells in patients with recurrent GBM. Just days after a single treatment, patients experienced dramatic reductions in their tumors, with one patient achieving near-complete tumor regression. In time, the researchers observed tumor progression in these patients, but given the strategy’s promising preliminary results, the team will pursue strategies to extend the durability of response.

“This is a story of bench-to-bedside therapy, with a novel cell therapy designed in the laboratories of Massachusetts General Hospital and translated for patient use within five years, to meet an urgent need,” said Bryan Choi, MD, PhD, neurosurgeon and associate director of the Center for Brain Tumor Immunology and Immunotherapy, Cellular Immunotherapy Program, Mass General Cancer Center and Department of Neurosurgery. “The CAR-T platform has revolutionized how we think about treating patients with cancer, but solid tumors like glioblastoma have remained challenging to treat because not all cancer cells are exactly alike and cells within the tumor vary. Our approach combines two forms of therapy, allowing us to treat glioblastoma in a broader, potentially more effective way.”

/* */